세계의 과민성 방광 치료 시장 예측(-2030년) : 유형별, 질병 유형별, 유통 채널별, 지역별 분석

According to Stratistics MRC, the Global Overactive Bladder Treatment Market is accounted for $3.6 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 6.2% during the forecast period. The condition known as overactive bladder (OAB) results in frequent, unexpected urinal urges that can be challenging to control. One can experience frequent urges to urinate during the day and at night, as well as inadvertent pee loss. A medical professional can identify overactive bladder by analyzing the symptoms and physically inspecting the organs close to the pelvic and rectum. Various treatments are available to treat hyperactive bladder. Changing certain behaviors, using medicine, and nerve stimulation are all possible treatments.

According to the article published in Krager Journal titled "Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation" for refractory overactive bladder, in June 2021, overactive bladder is highly prevalent worldwide and found that its overall prevalence was 11.8%.

Market Dynamics:

Driver:

Rising prevalence of neurological conditions

Several drugs, including antiepileptics, antipsychotics, analgesics, and anticholinergics, are used to treat neurological illnesses. The aging population is driving market expansion, along with increased spending on the development of new drugs and devices. Additionally, government regulatory agencies and private groups are projected to launch awareness efforts to raise public knowledge of early disorder diagnosis. Additionally, effective medications will soon enter the market as a result of a robust development pipeline, which is expected to fuel market expansion.

Restraint:

Frequent product recalls

A large portion of the population suffers from overactive bladder, a chronic medical condition that has an adverse effect on quality of life. The expansion of the market could be hampered in the coming years by frequent recalls of OAB-treating medications. Due to production problems, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US in June 2021. Leading pharmaceutical corporations frequently recalling their products hurts the market's expansion.

Opportunity:

Increasing R&D spending and the introduction of new treatments

Pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. In addition, more than 30 OAB candidates are presently in clinical development pathways. These are divided into three Phase II, seven Phase III, and sixteen Phase IV projects. The market for treating overactive bladder is anticipated to grow as a result of this strong pipeline and the eventual introduction of additional medications and therapies. Samsung Medical Center is researching potential biomarkers in OAB patients, including adenosine triphosphate (ATP), prostaglandin E2 (PGE2), and nerve growth factor (NGF). Players in the OAB treatment market can anticipate benefiting from significant growth prospects as a result of such advances.

Threat:

Lack of knowledge about its prevalence

One of the things preventing the market from expanding is the dearth of medications in Phase III development or the pre-registration stages. Additionally, throughout the forecast period, market expansion is hampered by the availability of complementary therapies, a lack of healthcare infrastructure in developing nations, and a shortage of qualified specialists. Recalls of products and stringent government regulations are also impeding industry expansion.

COVID-19 Impact:

The COVID-19 outbreak had a beneficial effect on the expansion of the overactive bladder sector globally. The patient's bladder dysfunction was greatly exacerbated by COVID-19 association cystitis (CAC), which also caused issues unique to other organs. This had a favorable effect on the market for treatments for overactive bladder both during and after the epidemic. The COVID-19 epidemic, on the other hand, presented one of the greatest difficulties for the healthcare system. Due to the protracted lockdown in important nations like the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of production facilities. This had some impact on the production of drugs for overactive bladder.

The anticholinergics segment is expected to be the largest during the forecast period

The anticholinergics segment is estimated to have a lucrative growth, due to the primary choice of medications for treating overactive bladder syndrome is anticholinergics. Additionally, the U.S. Food and Drug Administration's quick product approvals for generic medications support the expansion of the anticholinergic market. Additionally, it has been predicted that a movement in end users' preferences of botox treatment over invasive surgery or oral drugs will increase the segment's development potential in the overactive bladder therapeutics market over the course of the projection year.

The idiopathic overactive bladder segment is expected to have the highest CAGR during the forecast period

The idiopathic overactive bladder segment is anticipated to witness the highest CAGR growth during the forecast period, due to rising rates of idiopathic overactive bladder in patients and rising demand for overactive bladder drugs for the treatment of idiopathic overactive bladder. The sector for neurogenic overactive bladder, on the other hand, is anticipated to expand at the quickest rate during the forecast period due to the rise in neurological diseases, which is predicted to increase the incidence of overactive bladder.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its robust healthcare sector. In addition, factors such as reimbursement for overactive bladder treatment, an increasing incidence of the condition with advancing age, and the presence of significant industry players in the region. Moreover, the market is set to benefit from the growing elderly population, and the substantial presence of an aging demographic in the region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, due to the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India. Moreover, an increase in medical spending and the use of high-tech manufacturing techniques to enhance the production of drugs for treating overactive bladder with largest pharmaceutical sector and the largest supply of medicines, with easy access to a plentiful supply of raw materials for pharmaceutical product producers in this region. In addition, because of the expanding industrial infrastructure, rising disposable incomes, and established domestic company presence in the area.

Key players in the market:

Some of the key players profiled in the Overactive Bladder Treatment Market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc. , Cipla Ltd, Lupin, Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., AbbVie Inc., Alembic Pharmaceuticals Limited, Sumitomo Pharma Co., Ltd, Teva Pharmaceutical Industries Limited, Johnson & Johnson Services, Inc., Medtronic, Sanofi, Uro Medical, Urovant Sciences, Macleods Pharmaceuticals Ltd, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc. and Laborie

Key Developments:

In July 2022, Dr. Reddy's Laboratories introduced fesoterodine fumarate extended-release tablets, a therapeutic generic equivalent to Pfizer's Toviaz (fesoterodine fumarate) ER tablets in the United States for the treatment of overactive bladder.

In April 2022, Dr Reddy's launched generic Methylprednisolone Sodium Succinate for injection in US, The injection is the generic equivalent of SOLUMEDROL and has been approved by the US Food and Drug Administration (USFDA), the company said in a regulatory filing.

In May 2022, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., presented data from the Phase 3 EMPOWUR Extension Study of GEMTESA(vibegron) 75 mg overactive bladder therapy.

Treatments Covered:

• Anticholinergics
• Mirabegron
• BOTOX
• Neuromodulation
• Other Treatments

Disease Types Covered:

• Neurogenic Overactive Bladder
• Idiopathic Overactive Bladder
• Other Disease Types

Distribution Channels Covered:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Overactive Bladder Treatment Market, By Type

• 5.1 Introduction
• 5.2 Anticholinergics
  • 5.2.1 Darifenacin
  • 5.2.2 Fesoterodine
  • 5.2.3 Oxybutynin
  • 5.2.4 Solifenacin
  • 5.2.5 Tolterodine
  • 5.2.6 Trospium
  • 5.2.7 Other Anticholinergics
• 5.3 Mirabegron
• 5.4 BOTOX
• 5.5 Neuromodulation
• 5.6 Other Treatments

6 Global Overactive Bladder Treatment Market, By Disease Type

• 6.1 Introduction
• 6.2 Neurogenic Overactive Bladder
  • 6.2.1 Parkinson's disease
  • 6.2.2 Strokes
  • 6.2.3 Multiple Sclerosis
  • 6.2.4 Spinal Cord Injuries
• 6.3 Idiopathic Overactive Bladder
• 6.4 Other Disease Types

7 Global Overactive Bladder Treatment Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Drug Stores and Retail Pharmacies
• 7.4 Online Providers
• 7.5 Other Distribution Channels

8 Global Overactive Bladder Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Dr. Reddy's Laboratories Ltd
• 10.2 Pfizer Inc.
• 10.3 Cipla Ltd
• 10.4 Lupin
• 10.5 Sun Pharmaceutical Industries Ltd.
• 10.6 Astellas Pharma Inc.
• 10.7 AbbVie Inc.
• 10.8 Alembic Pharmaceuticals Limited
• 10.9 Sumitomo Pharma Co., Ltd
• 10.10 Teva Pharmaceutical Industries Limited
• 10.11 Johnson & Johnson Services, Inc.
• 10.12 Medtronic
• 10.13 Sanofi
• 10.14 Uro Medical
• 10.15 Urovant Sciences
• 10.16 Macleods Pharmaceuticals Ltd
• 10.17 Endo International PLC
• 10.18 Hisamitsu Pharmaceutical Co., Inc.
• 10.19 Laborie